All lobbying filings

ARNOLD & PORTER KAYE SCHOLER LLP

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $80,000.00 income · posted Apr 17, 2026

Official filing document

Bills named in this filing 2

HR 4231
Treat and Reduce Obesity Act of 2025
S 1973
Treat and Reduce Obesity Act of 2025

Lobbying activity 4

Pharmacy

Issues related to general compounding.

Health Issues

Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Consumer Issues/Safety/Products

Issues related to general compounding.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.